Ki Chung to Antibodies, Monoclonal, Humanized
This is a "connection" page, showing publications Ki Chung has written about Antibodies, Monoclonal, Humanized.
Connection Strength
0.222
-
Phase I study of two schedules of oral S-1 in combination with fixed doses of oxaliplatin and bevacizumab in patients with advanced solid tumors. Oncology. 2011; 81(2):65-72.
Score: 0.086
-
Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer. J Clin Oncol. 2010 Jul 20; 28(21):3485-90.
Score: 0.078
-
A Phase II Study of Durvalumab in Combination with Tremelimumab in Patients with Rare Cancers. Oncologist. 2021 09; 26(9):e1499-e1507.
Score: 0.042
-
Bevacizumab 5 mg/kg can be infused safely over 10 minutes. J Clin Oncol. 2007 Jul 01; 25(19):2691-5.
Score: 0.016